Wockhardt, a leading pharmaceutical and biotechnology major, announced that its Chicago-based arm Morton Grove Pharmaceuticals has got sanction from US Food and Drug Administration (USFDA) for selling an oral suspension of a combination of Amoxycillin and Clavulanate Potassium.

According to the sources, the said drug is indicated for the treatment of several common infections, especially in children. The product is marketed in the US by Glaxo SmithKline under the brand name Augmentin 250.